Company / Operating Cash Flow
TherapeuticsMD, Inc. Operating Cash Flow History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$23.1M
FY2024
5-year range
-$165.7M / $9.4M
FY2020-FY2024
Trend
-346.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow changed -347% YoY in FY2024, a notable deviation from the 9-year average annual change of -50%.
Based on SEC 10-K filings.
-$23M in FY2024.
Improved from -$55M to -$23M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating cash flow decreased 346.6% year-over-year.
- Peak operating cash flow was recorded in FY2023.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$23.1M | -346.6% |
| FY2023 | $9.4M | +117.0% |
| FY2022 | -$55.1M | +66.7% |
| FY2021 | -$165.7M | -55.1% |
| FY2020 | -$106.8M | -40.3% |
| FY2019 | -$76.2M | -10.1% |
| FY2018 | -$69.1M | +12.5% |
| FY2017 | -$79.0M | -73.6% |
| FY2016 | -$45.5M | -119.2% |
| FY2015 | -$20.8M | -63.0% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026